Early Implementation of Long-Acting Injectable Cabotegravir for HIV Prevention in a Safety Net Hospital-based Primary Care Center in U.S. South.

Advanced Search

Dylan Baker, Lauren F Collins, Valeria D Cantos, Emma Hollenberg, Alexander Kaplan, Terri Cowan, Jose Garcia, Meredith Lora

Author Information

Dylan Baker: Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. dylan.mathieu-henri.baker@emory.edu.
Lauren F Collins: Grady Health System, Atlanta, GA, USA.
Valeria D Cantos: Grady Health System, Atlanta, GA, USA.
Emma Hollenberg: Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Alexander Kaplan: Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Terri Cowan: Grady Health System, Atlanta, GA, USA.
Jose Garcia: Grady Health System, Atlanta, GA, USA.
Meredith Lora: Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. Meredith.lora@emory.edu. ORCID

PMID: 39934566 DOI: 10.1007/s11606-025-09350-8

BACKGROUND: Long-acting injectable cabotegravir (CAB-LA), approved in 2021, is a more effective HIV prevention method than daily oral PrEP. CAB-LA expansion addresses key HIV prevention gaps, especially in the Southern United States (U.S.), to support national Ending the HIV Epidemic (EHE) goals. However, complex implementation requirements hinder CAB-LA expansion, highlighting the need for real-world data to guide effective and equitable scale-up.
OBJECTIVE: Describe the implementation and early outcomes of implementing CAB-LA in a large safety-net primary care center in the Southern U.S.
DESIGN: We described the integration of CAB-LA into an existing oral PrEP program. We manually abstracted individual sociodemographic and clinical data. We developed a CAB-LA care continuum and reported early outcomes among CAB-LA initiators.
PARTICIPANTS: Individuals referred to the CAB-LA program from 12/1/2022 to 8/1/2023, with outcomes assessed through 12/1/2023.
MAIN MEASURES: Development of a CAB-LA care continuum from linkage, eligibility assessment, program enrollment, initiation, and persistence. We reported the sociodemographic and clinical characteristics of individuals referred for and initiated on CAB-LA, the total number and timing of injections administered, self-reported adverse events, CAB-LA discontinuations, and HIV seroconversions.
KEY RESULTS: Integration of CAB-LA into an existing oral PrEP program required multidisciplinary team adaptation, protocol development for drug procurement and care coordination, and adapting an existing population health registry to the CAB-LA workflow to monitor and track individuals. Of 221 referred individuals, 77 (35%) initiated CAB-LA. Initiation barriers included program intake scheduling delays (29%), individuals declining CAB-LA (19%), and delayed medication procurement (16%). Among CAB-LA initiators, 275 injections were administered, 94% were administered on time, six individuals (8%) reported adverse effects, and eight (10%) discontinued CAB-LA. No HIV seroconversions occurred.
CONCLUSIONS: We successfully implemented a CAB-LA PrEP program in a safety-net primary care center in the U.S. South, using an approach designed to address structural barriers to PrEP uptake and persistence.

HIV prevention U.S. South implementation science long-acting cabotegravir pre-exposure prophylaxis uptake

Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021;385(7):595-608. https://doi.org/10.1056/NEJMoa2101016 . [DOI: 10.1056/NEJMoa2101016]
Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779-89. https://doi.org/10.1016/S0140-6736(22)00538-4 . [DOI: 10.1016/S0140-6736(22)00538-4]
Chou R, Spencer H, Bougatsos C, Blazina I, Ahmed A, Selph S. Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023;330(8):746-63. https://doi.org/10.1001/jama.2023.9865 . [DOI: 10.1001/jama.2023.9865]
Calabrese SK. Understanding, Contextualizing, and Addressing PrEP Stigma to Enhance PrEP Implementation. Curr HIV/AIDS Rep. 2020;17(6):579-88. https://doi.org/10.1007/s11904-020-00533-y . [DOI: 10.1007/s11904-020-00533-y]
Serota DP, Rosenberg ES, Lockard AM, Rolle CM, Luisi N, Cutro S, et al. Beyond the Biomedical: Preexposure Prophylaxis Failures in a Cohort of Young Black Men Who Have Sex With Men in Atlanta, Georgia. Clin Infect Dis. 2018;67(6):965-70. https://doi.org/10.1093/cid/ciy297 . [DOI: 10.1093/cid/ciy297]
Prevention CfDCa. HV Surveillance Supplemental Report: Estimated HIV Incidence and Prevalence in the United States, 2018–2022 2024. Available from: https://stacks.cdc.gov/view/cdc/156513 . Accessed 23 Dec 2024.
Sullivan PS, Woodyatt C, Koski C, Pembleton E, McGuinness P, Taussig J, et al. A Data Visualization and Dissemination Resource to Support HIV Prevention and Care at the Local Level: Analysis and Uses of the AIDSVu Public Data Resource. J Med Internet Res. 2020;22(10):e23173. https://doi.org/10.2196/23173 . [DOI: 10.2196/23173]
Stansfield SE, Heitner J, Mitchell KM, Doyle CM, Milwid RM, Moore M, et al. Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis. J Int AIDS Soc. 2023;26 Suppl 2(Suppl 2):e26109. https://doi.org/10.1002/jia2.26109 . [DOI: 10.1002/jia2.26109]
Maloney KM, Le Guillou A, Driggers RA, Sarkar S, Anderson EJ, Malik AA, Jenness SM. Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral Human Immunodeficiency Virus Preexposure Prophylaxis: A Mathematical Model. J Infect Dis. 2021;223(1):72-82. https://doi.org/10.1093/infdis/jiaa552 . [DOI: 10.1093/infdis/jiaa552]
Balasubramanian R, Kasaie P, Schnure M, Dowdy DW, Shah M, Fojo AT. Projected Impact of Expanded Long-Acting Injectable PrEP Use Among Men Who Have Sex With Men on Local HIV Epidemics. J Acquir Immune Defic Syndr. 2022;91(2):144-50. https://doi.org/10.1097/qai.0000000000003029 . [DOI: 10.1097/qai.0000000000003029]
Tolley EE, Bula A, Chitukuta M, Ndimande-Khoza N, Etima J, Namey E, et al. Preferences for oral and injectable PrEP among qualitative sub-study participants in HPTN 084. PLoS ONE. 2024;19(10):e0309811. https://doi.org/10.1371/journal.pone.0309811 . [DOI: 10.1371/journal.pone.0309811]
Minnis AM, Browne EN, Boeri M, Agot K, van der Straten A, Ahmed K, et al. Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 2019;80(4):394-403. https://doi.org/10.1097/qai.0000000000001945 . [DOI: 10.1097/qai.0000000000001945]
Scott H, Hanscom B, Hutchinson C, Lucas J, Gaur A, Kelley C, et al. Cabotegravir for HIV PrEP in U.S. Black Men and Transgender Women Who Have Sex With Men. Conference on Retroviruses and Opportunistic Infections; Seattle, Washington 2023.
Koss CA, Parikh UM. Long-acting preexposure prophylaxis: early data on roll-out in the United States. Curr Opin HIV AIDS. 2025;20(1):25-31. https://doi.org/10.1097/coh.0000000000000894 . [DOI: 10.1097/coh.0000000000000894]
Mann LM, Zhu W, Huang YA, Kourtis AP, Fanfair RN, Hoover KW. Trends in Oral and Injectable HIV Preexposure Prophylaxis Prescriptions in the US, 2013-2023. Jama. 2024;332(18):1580-3. https://doi.org/10.1001/jama.2024.21493 . [DOI: 10.1001/jama.2024.21493]
Inc VH. Apretude Package Insert. Research Triange Park, NC2021.
Sharma I, Hill A. Global HIV Incidence Analysis and Implications for Affordability Using Long-Acting Cabotegravir Versus Continuous and Event-Driven Oral Preexposure Prophylaxis. Clin Infect Dis. 2024;78(2):386-94. https://doi.org/10.1093/cid/ciad537 . [DOI: 10.1093/cid/ciad537]
Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 Update: a clinical practice guideline. 2021. p. 1–108.
Serota DP, Rosenberg ES, Sullivan PS, Thorne AL, Rolle CM, Del Rio C, et al. Pre-exposure Prophylaxis Uptake and Discontinuation Among Young Black Men Who Have Sex With Men in Atlanta, Georgia: A Prospective Cohort Study. Clin Infect Dis. 2020;71(3):574-82. https://doi.org/10.1093/cid/ciz894 . [DOI: 10.1093/cid/ciz894]
Colson PW, Franks J, Wu Y, Winterhalter FS, Knox J, Ortega H, et al. Adherence to Pre-exposure Prophylaxis in Black Men Who Have Sex with Men and Transgender Women in a Community Setting in Harlem, NY. AIDS Behav. 2020;24(12):3436-55. https://doi.org/10.1007/s10461-020-02901-6 . [DOI: 10.1007/s10461-020-02901-6]
Sharpe JD, Siegler AJ, Sanchez TH, Guest JL, Sullivan PS. Effects of mode of transportation on PrEP persistence among urban men who have sex with men. AIDS Care. 2023;35(9):1411-9. https://doi.org/10.1080/09540121.2023.2217375 . [DOI: 10.1080/09540121.2023.2217375]
Barnett AP, Arnold T, Elwy AR, Brock JB, Giorlando KK, Sims-Gomillia C, et al. Considerations for PrEP Implementation at Federally Qualified Health Centers in Mississippi: Perspectives From Staff and Patients. AIDS Educ Prev. 2023;35(4):309-19. https://doi.org/10.1521/aeap.2023.35.4.309 . [DOI: 10.1521/aeap.2023.35.4.309]
McCain J. The Importance of a Thorough Benefits Investigation to Help Navigate Medical vs Pharmacy Benefit: National Association of Medication Access & Patient Advocacy; 2022 [12/23/2024]. Available from: https://www.namapa.org/medical-vs-pharmacy-benefit . Accessed 23 Dec 2024.
Spinelli MA, Bisom-Rapp E, Heise MJ, Camp C, Appa A, Liu AY, et al. High Retention and Adherence With Rapid Long-acting Injectable Preexposure Prophylaxis Implementation in an Urban Safety Net Clinic Population. Clin Infect Dis. 2024. https://doi.org/10.1093/cid/ciae531 . [DOI: 10.1093/cid/ciae531]
Hazra A, Schneider J, Murray M, Williams J, Halbur D, Creticos C. Insurance Type Drives Cabotegravir Delays: Real-World Long-Acting PrEP Outcomes in the Midwest US. Conference on Retroviruses and Opportunistic Infections; Denver, Colorado 2024.
Turner C, Wagner G, Pfeil A, Willcott A, LonerganT, Hill L, Blumenthal J. Implementing Long-Acting Cabotegravir for HIV Preexposure Prophylaxis in a Large Urban HIV Clinic. Conference on Retroviruses and Opportunistic Infections; Denver, Colorado 2024.
Collins LF, Corbin-Johnson D, Asrat M, Morton ZP, Dance K, Condra A, et al. Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South. Open Forum Infect Dis. 2022;9(9). https://doi.org/10.1093/ofid/ofac455 .
Johnson K, Sawkin MT. Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine. Drugs Context. 2022;11. https://doi.org/10.7573/dic.2021-9-2 .
Cooper SE, Rosenblatt J, Gulick RM. Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries. Clin Infect Dis. 2022;75(Supplement_4):S541-S8. https://doi.org/10.1093/cid/ciac716 . [DOI: 10.1093/cid/ciac716]
McCrimmon T, Collins LF, Perez-Brumer A, Bazzi AR, Shaffer VA, Kerrigan D, et al. Long-Acting Injectable Antiretrovirals for HIV Treatment: A Multi-Site Qualitative Study of Clinic-Level Barriers to Implementation in the United States. AIDS Patient Care STDS. 2024;38(2):61-9. https://doi.org/10.1089/apc.2023.0248 . [DOI: 10.1089/apc.2023.0248]
Agovi AM, Thompson CT, Craten KJ, Fasanmi E, Pan M, Ojha RP, Thompson EL. Patient and clinic staff perspectives on the implementation of a long-acting injectable antiretroviral therapy program in an urban safety-net health system. Implement Sci Commun. 2024;5(1):93. https://doi.org/10.1186/s43058-024-00631-7 . [DOI: 10.1186/s43058-024-00631-7]
Patel RR, Mayer KH. Why is roll-out of long-acting PrEP agents so slow? Curr Opin HIV AIDS. 2025;20(1):48-53. https://doi.org/10.1097/coh.0000000000000899 . [DOI: 10.1097/coh.0000000000000899]
Altamirano JA, Shukla P, Barnett SK. 1531. Early Real-World Experience of Long-Acting Cabotegravir (CAB) for HIV Pre-Exposure Prophylaxis (PrEP) in a Large Community-Based Clinic Network (CAN Community Health): Utilization and PrEP Persistence. Open Forum Infect Dis. 2023;10(Supplement_2). https://doi.org/10.1093/ofid/ofad500.1366 .
Harris N, DeSilva K, Kuriakose R, Sorlie S, Reed S, Oliver N, Moanna A, Webster A, Cartwright E. Implementation and Uptake of Long-Acting Injectable PrEP at Atlanta VA Healthcare System. Infectious Diseases Week; Los Angeles, California 2024.
Gonzalez J, Rebolledo PA, Siegler AJ, Huang W, Mayer KH, Cantos VD. Development of a home-based pre-exposure prophylaxis care delivery system for long-acting injectable cabotegravir: a formative exploration of patient preferences. AIDS Care. 2024;36(12):1882-90. https://doi.org/10.1080/09540121.2024.2397128 . [DOI: 10.1080/09540121.2024.2397128]
Kirk SE, Young C, Berry H, Hanson R, Moreland A, Fonner V, et al. Comparison of At-Home Versus In-Clinic Receipt of Long-Acting Injectable Cabotegravir/Rilpivirine. Clin Infect Dis. 2024. https://doi.org/10.1093/cid/ciae472 . [DOI: 10.1093/cid/ciae472]

Journal Article

OpenLB
Open Library of Bioscience